Recent News

• 03.11.2025 - Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
• 03.10.2025 - Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
• 03.09.2025 - Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
• 02.27.2025 - Trevi Therapeutics to Participate in Upcoming March Investor Conferences
• 02.25.2025 - Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
• 01.30.2025 - Trevi Therapeutics to Participate in Upcoming February Investor Conferences
• 01.08.2025 - Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

Recent Filings

• 03.10.2025 - 8-K Current report
• 03.10.2025 - 144 Report of proposed sale of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors